|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells.
|
28351036 |
2017 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling.
|
24608429 |
2015 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conclude that NSCLC in contrast to SCLC expresses high levels of EGF receptors which may be used to facilitate the differential diagnosis in some cases of lung cancer.
|
2830015 |
1988 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Little is known about lung carcinoma epidermal growth factor (EGF) kinase pathway signaling within the context of the tissue microenvironment.
|
18687633 |
2008 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, SP-D has been shown to suppress lung cancer progression <i>via</i> interference with the epidermal growth factor signaling.
|
30127783 |
2018 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Collectively, our in vivo and in vitro findings support that TWIST1 collaborates with the EGF pathway in promoting EMT in EGFR mutated lung adenocarcinoma and that large series of EGFR mutated lung cancer patients are needed to further define the prognostic role of TWIST1 reactivation in this subgroup.
|
22272264 |
2012 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We created a proof-of-principle database [DNA-mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT)], starting with lung cancer-associated EGF receptor (EGFR) mutations, to provide a resource for clinicians to prioritize treatment decisions based on a patient's tumor mutations at the point of care.
|
23344264 |
2013 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results of multiple clinical trials suggest that EGF receptor (EGFR) tyrosine kinase inhibitors (TKI) exhibit negative effects on platinum-based chemotherapy in patients with lung cancer with wild-type (WT) EGFR, but the underlying molecular mechanisms are still uncertain.
|
23344263 |
2013 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potential ligand-binding sites within the epidermal growth factor (EGF)-like repeats of Notch1 have been identified, but the ligand-binding domains in Notch3, which is implicated in lung cancer, are not known.
|
20068176 |
2010 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor (EGF)/DNA complexes targeted to cancer cells overexpressing the EGF receptor resulted in efficient transduction of several lung cancer cell lines in vitro.
|
9727626 |
1998 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Smoking patients with lung cancer with EBs were significantly younger (63.6 versus 67.7 years, p = 0.0179) and had tumors with a lower frequency of epidermal growth factor gene (EGFR) mutations (3.8% versus 24.2%, p = 0.0184) compared with those without EBs.
|
27164304 |
2016 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The authors have previously shown that DAB(389)EGF is selectively toxic to EGFR-overexpressing cells, including human brain tumour and lung carcinoma cell lines.
|
14519080 |
2003 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.
|
24063894 |
2013 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
|
25653196 |
2015 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer is one of the leading cause of cancer death worldwide, the most common histological type of lung cancer is non-small cell lung cancer (NSCLC), whose occurrence and development is closely related to the mutation and amplification of epidermal growth factor receptors (EGFR).
|
30868964 |
2019 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGF could trigger resistance to RET inhibition in CCDC6-RET lung cancer cells, and endothelial cells may confer resistance to RET inhibitors by EGF.
|
27873490 |
2017 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with advanced or metastatic forms of lung cancer with an activating mutation in <i>epidermal growth factor receptor</i> (<i>EGFR</i>) are given tyrosine kinase inhibitors (TKIs) targeted therapies that are more efficient than chemotherapy.
|
30775029 |
2019 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population.
|
15663953 |
2005 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, we found that EGF-induced EGFR endocytosis is existed differently between gefitinib-sensitive and -insensitive lung cancer cell lines.
|
24658031 |
2014 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To establish and develop a reliable and simple Real-time PCR assay with high resolution melting (Real-time PCR-HRM) method for detection epidermal growth factor (EGFR) and BIM mutation of lung cancer and looking for effective targeted drugs to control lung cancer.
|
27424979 |
2016 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.
|
24019492 |
2013 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A test to predict outcome after treatment with an epidermal growth factor rector/tyrosine kinase inhibitor and a screening blood test for lung cancer are being investigated for use in proteomic profiling.
|
24357739 |
2014 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.
|
25468140 |
2015 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the EGF+61 A>G polymorphism may not significantly affect the susceptibility to lung cancer in the Korean population.
|
17986122 |
2007 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistent with the role of NEDD4, cathepsin B is pivotal for both basal and the EGF-stimulated lung cancer cell migration.
|
29455656 |
2018 |